Cancer

Vitamin-based PD-1 pathway blockade for Human cancer therapy: Cholecalciferol, a form of Vitamin-D3, decreases the expression of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 17 June, 2017, 12.23 am
Vitamin-based PD-1 pathway blockade for Human cancer therapy: Cholecalciferol, a form of Vitamin-D3, decreases the expression of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 17 June, 2017, 12.23 am 150 150 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say:  A recent study from Cell Signalling Section, Division of Immunology, Department of Pathology, Tennis Court Road, University of Cambridge, Cambridge CB2 1QP, UK shows that “Glycogen Synthase…

read more

Combination therapy for enhancing the efficacy of tyrosine-kinase inhibitor (TKI) in BCR-ABL-induced Human leukemia: A therapeutic mix encompassing Ascorbate and Forodesine decreases the expression of oncoproteins c-FOS, DUSP1 and BCR-ABL, inhibits TKI resistance, restores treatment responsiveness, increases therapeutic index of anticancer drugs, and cure CML and kinase-driven cancers via up-regulation of its target gene, 16/June/2017, 2.05 am
Combination therapy for enhancing the efficacy of tyrosine-kinase inhibitor (TKI) in BCR-ABL-induced Human leukemia: A therapeutic mix encompassing Ascorbate and Forodesine decreases the expression of oncoproteins c-FOS, DUSP1 and BCR-ABL, inhibits TKI resistance, restores treatment responsiveness, increases therapeutic index of anticancer drugs, and cure CML and kinase-driven cancers via up-regulation of its target gene, 16/June/2017, 2.05 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Division of Experimental Hematology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Division of Pathology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio,…

read more

Interleukin therapy for Chronic Myeloid leukaemia (CML): Interleukin-1β decreases the expression of Musashi2, inhibits cytosolic aminotransferase BCAT1 expression, decreases the intracellular production of BCAAs (Branched-chain amino acids), increases the expression of tumor suppressor genes, promotes differentiation of CML cells, and inhibits cancer progression in Myeloid leukemia via up-regulation of its target gene, 15/June/2017, 11.48 pm
Interleukin therapy for Chronic Myeloid leukaemia (CML): Interleukin-1β decreases the expression of Musashi2, inhibits cytosolic aminotransferase BCAT1 expression, decreases the intracellular production of BCAAs (Branched-chain amino acids), increases the expression of tumor suppressor genes, promotes differentiation of CML cells, and inhibits cancer progression in Myeloid leukemia via up-regulation of its target gene, 15/June/2017, 11.48 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Department of Biochemistry-Molecular Biology, Franklin College of Arts and Sciences, The University of Georgia, Athens, Georgia 30602, USA; and The University of…

read more

Natural product-derived Anti-AXL therapeutics for enhancing the efficacy of chemotherapies: Combination of Honokiol and Hesperidin, found in Magnolia grandiflora and Citrus fruits, respectively, decreases the expression of the AXL receptor and its activating ligand, GAS6, increases the expression of a number of tumor suppressor genes, increases therapeutic index of anticancer drugs, suppresses tumorigenesis, migration, invasion, and metastasis via up regulation of its target gene, 15/June/2017, 1.00 am
Natural product-derived Anti-AXL therapeutics for enhancing the efficacy of chemotherapies: Combination of Honokiol and Hesperidin, found in Magnolia grandiflora and Citrus fruits, respectively, decreases the expression of the AXL receptor and its activating ligand, GAS6, increases the expression of a number of tumor suppressor genes, increases therapeutic index of anticancer drugs, suppresses tumorigenesis, migration, invasion, and metastasis via up regulation of its target gene, 15/June/2017, 1.00 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Department of Radiation Oncology, Stanford University School of Medicine shows that “Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies.” This…

read more

Molecular therapy for Chronic Myeloid leukaemia (CML): Resistin decreases the expression of Musashi2, inhibits cytosolic aminotransferase BCAT1 expression, decreases the intracellular production of BCAAs (Branched-chain amino acids), increases the expression of tumor suppressor genes, promotes differentiation of CML cells, and inhibits cancer progression in Myeloid leukemia via up-regulation of its target gene, 13/June/2017, 11.59 p
Molecular therapy for Chronic Myeloid leukaemia (CML): Resistin decreases the expression of Musashi2, inhibits cytosolic aminotransferase BCAT1 expression, decreases the intracellular production of BCAAs (Branched-chain amino acids), increases the expression of tumor suppressor genes, promotes differentiation of CML cells, and inhibits cancer progression in Myeloid leukemia via up-regulation of its target gene, 13/June/2017, 11.59 p 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Department of Biochemistry-Molecular Biology, Franklin College of Arts and Sciences, The University of Georgia, Athens, Georgia 30602, USA; and The University of…

read more

Natural product-derived therapy for metastatic prostate cancer: Cucurbitacin D, isolated from Trichosanthes Kirilowii, and Phormum tenax among others, inhibits the expression of CDC42, CDC42EP3, RAC1 and ARPC5, and GAS6, suppresses the expression of stem cell molecules CD44 and EZH2, promotes epithelial phenotype, suppresses tumorigenesis, migration, invasion, stem cell regeneration and metastasis via up regulation of its target gene, 12/June/2017, 11.39 pm
Natural product-derived therapy for metastatic prostate cancer: Cucurbitacin D, isolated from Trichosanthes Kirilowii, and Phormum tenax among others, inhibits the expression of CDC42, CDC42EP3, RAC1 and ARPC5, and GAS6, suppresses the expression of stem cell molecules CD44 and EZH2, promotes epithelial phenotype, suppresses tumorigenesis, migration, invasion, stem cell regeneration and metastasis via up regulation of its target gene, 12/June/2017, 11.39 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Science Park, Texas 78957, USA shows that “MicroRNA-141 suppresses…

read more
Start Typing